Dr Kimberly Blackwell interviewed by Professor David Miles, Mount Vernon Hospital, London, UK, about the EMILIA trial at the ASCO 2012 Annual Meeting in Chicago, June 2012.

The EMILIA trial is a phase III randomised study of the investigational agent trastuzumab emtansine (T-DM1) vs. standard therapy using capecitabine and lapatinib.

Dr Blackwell and her team found significant and clinically meaningful improvement in progression-free survival with T-DM1 in women with HER2-positive locally advanced or metastatic breast cancer previously treated with a taxane and trastuzumab.